RU2011133335A - Способы и композиции для лечения персистирующих инфекций - Google Patents
Способы и композиции для лечения персистирующих инфекций Download PDFInfo
- Publication number
- RU2011133335A RU2011133335A RU2011133335/15A RU2011133335A RU2011133335A RU 2011133335 A RU2011133335 A RU 2011133335A RU 2011133335/15 A RU2011133335/15 A RU 2011133335/15A RU 2011133335 A RU2011133335 A RU 2011133335A RU 2011133335 A RU2011133335 A RU 2011133335A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- antibody
- antigen
- composition according
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
1. Композиция для смягчения или предотвращения персистирующей инфекции, ангиоиммунобластической лимфомы или нодулярной с лимфоидным преобладанием лимфомы Ходжкина, содержащая ингибитор активности или экспрессии PD-1.2. Композиция по п.1, где указанный ингибитор активности или экспрессии PD-1 понижает экспрессию или активность PD-L1.3. Композиция по п.2, где указанный ингибитор активности или экспрессии PD-1 представляет собой антитело к PD-L1.4. Композиция по п.3, где указанная персистирующая инфекция представляет собой вирус иммунодефицита человека, Т-лимфотрофический вирус человека, вирус герпеса, вирус Эпштейна-Барр или вирус папилломы человека.5. Композиция по п.3, где указанная персистирующая инфекция представляет собой инфекцию вирусом иммунодефицита человека.6. Композиция по п.5, дополнительно содержащая вакцину.7. Композиция по п.6, где указанная вакцина вызывает иммунный ответ в отношении вируса иммунодефицита человека.8. Композиция по п.1, приготовленная для имплантации.9. Композиция по п.1, приготовленная для системного введения.10. Композиция по п.1, приготовленная для парентерального введения.11. Композиция по п.1, дополнительно содержащая противовирусный агент.12. Композиция по п.1, где указанный ингибитор PD-1 представляет собой антитело к PD-1, антитело к PD-L1, антитело к PD-L2, анти-PD-1-РНКи, анти-PD-L1-РНКи, анти-PD-L2-РНКи, анти-PD-1-антисмысловая РНК, анти-PD-L1-антисмысловая РНК, анти-PD-L2-антисмысловая РНК, доминантно-негативный белок PD-1, доминантно-негативный белок PD-L1 или доминантно-негативный белок PD-L2.13. Композиция по п.3, где указанное антитело к PD-L1 представляет собой моноклональное антитело или гуманизированное моноклональн
Claims (21)
1. Композиция для смягчения или предотвращения персистирующей инфекции, ангиоиммунобластической лимфомы или нодулярной с лимфоидным преобладанием лимфомы Ходжкина, содержащая ингибитор активности или экспрессии PD-1.
2. Композиция по п.1, где указанный ингибитор активности или экспрессии PD-1 понижает экспрессию или активность PD-L1.
3. Композиция по п.2, где указанный ингибитор активности или экспрессии PD-1 представляет собой антитело к PD-L1.
4. Композиция по п.3, где указанная персистирующая инфекция представляет собой вирус иммунодефицита человека, Т-лимфотрофический вирус человека, вирус герпеса, вирус Эпштейна-Барр или вирус папилломы человека.
5. Композиция по п.3, где указанная персистирующая инфекция представляет собой инфекцию вирусом иммунодефицита человека.
6. Композиция по п.5, дополнительно содержащая вакцину.
7. Композиция по п.6, где указанная вакцина вызывает иммунный ответ в отношении вируса иммунодефицита человека.
8. Композиция по п.1, приготовленная для имплантации.
9. Композиция по п.1, приготовленная для системного введения.
10. Композиция по п.1, приготовленная для парентерального введения.
11. Композиция по п.1, дополнительно содержащая противовирусный агент.
12. Композиция по п.1, где указанный ингибитор PD-1 представляет собой антитело к PD-1, антитело к PD-L1, антитело к PD-L2, анти-PD-1-РНКи, анти-PD-L1-РНКи, анти-PD-L2-РНКи, анти-PD-1-антисмысловая РНК, анти-PD-L1-антисмысловая РНК, анти-PD-L2-антисмысловая РНК, доминантно-негативный белок PD-1, доминантно-негативный белок PD-L1 или доминантно-негативный белок PD-L2.
13. Композиция по п.3, где указанное антитело к PD-L1 представляет собой моноклональное антитело или гуманизированное моноклональное антитело.
14. Композиция по п.3, где указанная композиция повышает вирусный клиренс.
15. Композиция по п.3, дополнительно содержащая антитело к CTLA-4, антитело к BTLA, антитело к CD28, антитело к ICOS, антитело к ICOS-L, антитело к B7-H3 или антитело к B7-H4.
16. Композиция для использования в способе смягчения или предотвращения персистирующей инфекции, ангиоиммунобластической лимфомы или нодулярной с лимфоидным преобладанием лимфомы Ходжкина, содержащая антиген-специфичную Т-клетку, приведенную в контакт с соединением, которое понижает экспрессию или активность PD-1, для понижения экспрессии или активности PD-1 в указанной антиген-специфичной Т-клетке.
17. Композиция по п.16, дополнительно содержащая антиген-специфичную В-клетку, приведенную в контакт с соединением, которое понижает экспрессию или активность PD-1, для понижения экспрессии или активности PD-1 в указанной антиген-специфичной В-клетке.
18. Композиция по п.16, где указанная антиген-специфичная Т-клетка является специфичной в отношении вирусного антигена.
19. Композиция по п.16, где указанная антиген-специфичная Т-клетка является специфичной в отношении антигена ангиоиммунобластической лимфомы или нодулярной с лимфоидным преобладанием лимфомы Ходжкина.
20. Композиция по п.18, где указанный вирусный антиген представляет собой антиген вируса иммунодефицита человека (ВИЧ), Т-лимфотрофического вируса человека, вируса герпеса, вируса Эпштейна-Барр или вируса папилломы человека.
21. Композиция по п.20, где указанный вирусный антиген представляет собой антиген вируса иммунодефицита человека.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68887205P | 2005-06-08 | 2005-06-08 | |
US60/688,872 | 2005-06-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007147642/15A Division RU2434641C2 (ru) | 2005-06-08 | 2006-06-08 | Способ и композиции для лечения персистирующих инфекций |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016131170A Division RU2746383C2 (ru) | 2005-06-08 | 2016-07-28 | Способы и композиции для лечения персистирующих инфекций |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011133335A true RU2011133335A (ru) | 2013-02-20 |
RU2596491C2 RU2596491C2 (ru) | 2016-09-10 |
Family
ID=37499143
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011133335/15A RU2596491C2 (ru) | 2005-06-08 | 2006-06-08 | Способы и композиции для лечения персистирующих инфекций |
RU2007147642/15A RU2434641C2 (ru) | 2005-06-08 | 2006-06-08 | Способ и композиции для лечения персистирующих инфекций |
RU2016131170A RU2746383C2 (ru) | 2005-06-08 | 2016-07-28 | Способы и композиции для лечения персистирующих инфекций |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007147642/15A RU2434641C2 (ru) | 2005-06-08 | 2006-06-08 | Способ и композиции для лечения персистирующих инфекций |
RU2016131170A RU2746383C2 (ru) | 2005-06-08 | 2016-07-28 | Способы и композиции для лечения персистирующих инфекций |
Country Status (24)
Country | Link |
---|---|
US (4) | US8652465B2 (ru) |
EP (5) | EP2397155B1 (ru) |
JP (7) | JP5788632B2 (ru) |
KR (4) | KR101514463B1 (ru) |
CN (3) | CN104436190A (ru) |
AU (1) | AU2006254902B8 (ru) |
BR (1) | BRPI0611766A2 (ru) |
CA (2) | CA2981431C (ru) |
CY (1) | CY1118612T1 (ru) |
DK (2) | DK1907000T4 (ru) |
ES (2) | ES2608316T3 (ru) |
HK (1) | HK1115326A1 (ru) |
HU (1) | HUE030877T2 (ru) |
IL (5) | IL187999A (ru) |
LT (1) | LT2397156T (ru) |
MX (2) | MX351401B (ru) |
NZ (4) | NZ593388A (ru) |
PL (2) | PL1907000T5 (ru) |
PT (1) | PT2397156T (ru) |
RU (3) | RU2596491C2 (ru) |
SG (1) | SG10201702670VA (ru) |
SI (2) | SI2397156T1 (ru) |
WO (1) | WO2006133396A2 (ru) |
ZA (1) | ZA200710975B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2723050C2 (ru) * | 2013-05-02 | 2020-06-08 | Анаптисбайо, Инк. | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) |
Families Citing this family (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ517122A (en) * | 1999-08-23 | 2004-02-27 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
PT1210428E (pt) * | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
PL1810026T3 (pl) * | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
KR101514463B1 (ko) | 2005-06-08 | 2015-04-28 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
AU2006321553B2 (en) * | 2005-12-08 | 2012-03-08 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to O8E |
US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
NZ574580A (en) * | 2006-08-21 | 2011-12-22 | Hoffmann La Roche | Her2 tumor therapy with an anti-vegf antibody |
CA2668800A1 (en) * | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7 and antibodies that bind thereto |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
CA3045637A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
WO2008083239A2 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
AU2014268176B2 (en) * | 2006-12-27 | 2016-03-31 | Dana-Farber Cancer Institute, Inc | Compositions and methods for the treatment of infections and tumors |
AU2013200388B2 (en) * | 2006-12-27 | 2014-10-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of infections and tumors |
CA2688061A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
CA2691357C (en) * | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
EP2170946A2 (en) | 2007-07-13 | 2010-04-07 | The Johns Hopkins University | B7-dc variants |
US8062852B2 (en) * | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
WO2009114335A2 (en) * | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
EP2317992A2 (en) | 2008-07-24 | 2011-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2324055A2 (en) * | 2008-08-25 | 2011-05-25 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
PL2344540T3 (pl) | 2008-10-02 | 2018-05-30 | Aptevo Research And Development Llc | Białka wiążące wiele celów antagonistyczne względem cd86 |
US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
CA2743464A1 (en) | 2008-11-14 | 2010-05-20 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
CN102282265B (zh) * | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010101249A1 (ja) * | 2009-03-06 | 2010-09-10 | 国立大学法人三重大学 | T細胞の機能増強方法 |
US20120064096A1 (en) * | 2009-03-17 | 2012-03-15 | Universite De La Mediterranee | BTLA Antibodies and Uses Thereof |
CN102448458B (zh) | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
AU2010286361A1 (en) | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
WO2011097345A1 (en) * | 2010-02-04 | 2011-08-11 | Virostatics Srl | Ki-67 assay for patient immune system status |
WO2011100841A1 (en) * | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
NZ602634A (en) | 2010-03-26 | 2015-06-26 | Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP2595613B1 (en) | 2010-07-22 | 2019-01-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Compounds for use in a method of preventing or treating viral infection |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
CN107266584B (zh) * | 2011-07-29 | 2022-05-13 | 宾夕法尼亚大学董事会 | 转换共刺激受体 |
US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
JP2014532053A (ja) | 2011-09-30 | 2014-12-04 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 治療用ペプチド |
MX349036B (es) | 2011-12-06 | 2017-07-07 | Univ Leland Stanford Junior | Metodos y composiciones para tratar enfermedades virales. |
WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
RU2705301C2 (ru) | 2012-02-16 | 2019-11-06 | Влп Терапьютикс, Ллк | Композиция вирусоподобных частиц |
US9603800B2 (en) | 2012-04-12 | 2017-03-28 | Yale University | Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels |
CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
WO2013177102A2 (en) * | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
US9845356B2 (en) * | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
EP2892558B1 (en) | 2012-09-07 | 2019-04-10 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-l1阻害剤併用療法を必要とする患者の同定 |
KR20150100716A (ko) | 2012-12-19 | 2015-09-02 | 앰플리뮨, 인크. | 항 인간 b7-h4 항체 및 이의 용도 |
US20150377891A1 (en) | 2013-02-07 | 2015-12-31 | (Institute National De La Santé Et De La Rechere Médicale) | Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas |
EP3292873B1 (en) | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
SG10201710472PA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN105142668B (zh) | 2013-03-15 | 2018-04-27 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
CN110079599B (zh) | 2013-03-15 | 2024-06-04 | 豪夫迈·罗氏有限公司 | 治疗pd-1和pd-l1相关疾患的生物标志物和方法 |
WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
CN105683217B (zh) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | 与pd-1结合的抗原结合蛋白 |
TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Vlp醫療股份有限公司 | 包含pd-1抗原或pd-1配體抗原的類病毒粒子 |
WO2015038538A1 (en) * | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
EP3062779B1 (en) | 2013-11-01 | 2024-06-12 | Yale University | Modular particles for immunotherapy |
JP6705746B2 (ja) * | 2013-12-06 | 2020-06-03 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 治療用ペプチド |
DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
JP6590810B2 (ja) | 2013-12-24 | 2019-10-16 | ヤンセン ファーマシューティカ エヌブイ | 抗vista抗体および断片 |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
EP3925973A1 (en) | 2014-03-14 | 2021-12-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
US11230719B2 (en) * | 2014-03-26 | 2022-01-25 | Denovo Biopharma Llc | Retroviral vector having immune-stimulating activity |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
MX2016016310A (es) | 2014-06-11 | 2017-10-20 | A Green Kathy | Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral. |
RS60097B1 (sr) | 2014-06-19 | 2020-05-29 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
MX2017000419A (es) | 2014-07-11 | 2017-08-16 | Genentech Inc | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. |
KR102504758B1 (ko) | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
ES2909957T3 (es) | 2014-07-16 | 2022-05-11 | Transgene | Virus oncolítico para la expresión de moduladores de puntos de control inmunitarios |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
DK3177644T3 (da) | 2014-08-05 | 2021-01-11 | MabQuest SA | Immunologiske reagenser, som binder til PD-1 |
WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
WO2016021209A1 (en) | 2014-08-08 | 2016-02-11 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein e3 |
AU2015301753B2 (en) | 2014-08-12 | 2021-04-08 | Massachusetts Institute Of Technology | Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein |
CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
CN115040532A (zh) | 2014-10-10 | 2022-09-13 | 伊黛拉制药有限公司 | 使用tlr9激动剂与检查点抑制剂对癌症的治疗 |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
CA2964363A1 (en) | 2014-10-17 | 2016-04-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators |
MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
WO2016121574A1 (ja) * | 2015-01-29 | 2016-08-04 | コニカミノルタ株式会社 | 相互作用する分子を有する血中細胞の同時検出方法 |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
US10023635B2 (en) | 2015-03-23 | 2018-07-17 | Jounce Therapeutics, Inc. | Antibodies to ICOS |
WO2016162867A1 (en) * | 2015-04-08 | 2016-10-13 | Efranat Ltd. | Combination therapy of macrophage activating factor and pd-1 signaling inhibitors |
SI3292153T1 (sl) | 2015-05-04 | 2020-01-31 | Affimed Gmbh | Kombinacija CD30XCD16A protitelesa z ANTI-PD-1 antagonističnim protitelesom za terapijo |
EP3090751A1 (en) * | 2015-05-06 | 2016-11-09 | Université de Lausanne | Molecular profiling of cd8 t-cells in autochthonous melanoma identifies maf as driver of exhaustion |
AU2016271142A1 (en) | 2015-05-29 | 2017-11-23 | Genentech, Inc. | PD-L1 promoter methylation in cancer |
CN113603784A (zh) | 2015-05-29 | 2021-11-05 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
JP7026509B2 (ja) | 2015-06-24 | 2022-02-28 | ヤンセン ファーマシューティカ エヌブイ | 抗vista抗体およびフラグメント |
EP3322731B1 (en) * | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
SI3456346T1 (sl) | 2015-07-30 | 2021-11-30 | Macrogenics, Inc. | Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh |
WO2017025498A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
EP3334763A4 (en) | 2015-08-11 | 2019-04-03 | Wuxi Biologics (Cayman) Inc. | NOVEL ANTI-PD-1 ANTIBODIES |
WO2017031760A1 (zh) * | 2015-08-27 | 2017-03-02 | 杨光华 | 干涉片段及其应用 |
WO2017031761A1 (zh) * | 2015-08-27 | 2017-03-02 | 杨光华 | 干涉片段及其应用 |
EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
EP3355920A4 (en) | 2015-09-29 | 2019-05-15 | Celgene Corporation | PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF |
LT3356411T (lt) | 2015-10-02 | 2021-09-10 | F. Hoffmann-La Roche Ag | Bispecifiniai antikūnai, specifiniai pd1 ir tim3 |
HUE056033T2 (hu) | 2015-10-02 | 2022-01-28 | Hoffmann La Roche | Anti-pd1 antitestek és felhasználási módszerek |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
AU2016342269A1 (en) | 2015-10-22 | 2018-03-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
JP2019500893A (ja) | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用 |
GEP20217328B (en) | 2015-12-14 | 2021-12-10 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
WO2017125815A2 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
EP3411407B1 (en) * | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
TW202216201A (zh) | 2016-02-12 | 2022-05-01 | 比利時商楊森製藥公司 | 抗vista抗體及片段、其用途及鑑定其之方法 |
US20170252417A1 (en) | 2016-03-07 | 2017-09-07 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
UA127432C2 (uk) * | 2016-03-14 | 2023-08-23 | Ф. Хоффманн-Ля Рош Аг | Олігонуклеотид для зниження експресії pd-l1 |
US10947317B2 (en) | 2016-03-15 | 2021-03-16 | Mersana Therapeutics, Inc. | NaPi2b-targeted antibody-drug conjugates and methods of use thereof |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
RU2021111187A (ru) | 2016-04-15 | 2021-04-29 | Янссен Фармасьютикалз, Инк. | Антитела против человеческого vista и их применение |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
MX2019000252A (es) | 2016-06-30 | 2019-10-09 | Oncorus Inc | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
CN109789197A (zh) | 2016-08-03 | 2019-05-21 | 奈斯科尔公司 | 用于调节lair信号转导的组合物和方法 |
RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
US11701357B2 (en) | 2016-08-19 | 2023-07-18 | Beigene Switzerland Gmbh | Treatment of B cell cancers using a combination comprising Btk inhibitors |
JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与 |
EP3512563A1 (en) | 2016-09-16 | 2019-07-24 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
CN109952317A (zh) | 2016-09-19 | 2019-06-28 | 细胞基因公司 | 使用pd-1结合蛋白治疗免疫病症的方法 |
CN106480027A (zh) * | 2016-09-30 | 2017-03-08 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA |
JP7288854B2 (ja) * | 2016-10-07 | 2023-06-08 | セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー | がんを治療するための新規アプローチ |
BR112019008859A2 (pt) | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra a morte programada 1 (pd-1) |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
KR102603681B1 (ko) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | 항체 및 이의 사용방법 |
CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
US10603358B2 (en) * | 2017-01-10 | 2020-03-31 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator |
WO2018134279A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF |
KR102089371B1 (ko) * | 2017-01-26 | 2020-03-16 | 사회복지법인 삼성생명공익재단 | 혈관면역아세포성 t 세포 림프종 진단용 마커 및 이의 용도 |
TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
KR20190121816A (ko) | 2017-04-03 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
CN110720039A (zh) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Lag-3阳性肿瘤的治疗 |
EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
CN110799543A (zh) | 2017-06-26 | 2020-02-14 | 百济神州有限公司 | 肝细胞癌的免疫治疗 |
CN107253988B (zh) * | 2017-07-19 | 2021-01-29 | 福州大学 | 一种人源程序性死亡因子配体pd-l2蛋白的制备方法 |
CR20200138A (es) | 2017-08-25 | 2020-06-14 | Five Prime Therapeutics Inc | Anticuerpos de b7-h4 y métodos para usarlos |
CN107596374B (zh) * | 2017-09-01 | 2020-06-30 | 广东医科大学 | B12蛋白表达抑制剂及其在结核病免疫和治疗中应用 |
WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
TW201929908A (zh) | 2017-12-21 | 2019-08-01 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯抗體共軛物 |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
CN112566934A (zh) | 2018-01-23 | 2021-03-26 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
WO2019149716A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
CN108530537B (zh) * | 2018-03-29 | 2019-07-02 | 中国人民解放军军事科学院军事医学研究院 | Pd-1/pd-l1信号通路抑制剂 |
WO2019207942A1 (ja) * | 2018-04-27 | 2019-10-31 | OTA Takayo | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー |
EP3810109A4 (en) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING CD73 |
WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
AU2019328632A1 (en) | 2018-08-27 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof |
WO2020047345A1 (en) | 2018-08-31 | 2020-03-05 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
CN112672759B (zh) * | 2018-09-29 | 2023-05-30 | 四川科伦博泰生物医药股份有限公司 | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 |
EA202191175A1 (ru) | 2018-10-29 | 2021-09-08 | Мерсана Терапьютикс, Инк. | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры |
US10952996B2 (en) | 2018-12-11 | 2021-03-23 | Theravance Biopharma R&D Ip, Llc | ALK5 inhibitors |
CN110092826B (zh) * | 2019-02-28 | 2022-04-15 | 天津大学 | CTLA-4类似物CFN13及CFN13-Fc基因和蛋白 |
CN110452870A (zh) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品 |
MA56533A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 |
JP2022536850A (ja) | 2019-06-18 | 2022-08-19 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | B型肝炎ウイルス(hbv)ワクチンおよび抗pd-1または抗pd-l1抗体の組合せ |
TW202132297A (zh) | 2019-11-22 | 2021-09-01 | 美商施萬生物製藥研發Ip有限責任公司 | 經取代吡啶及使用方法 |
US20210154281A1 (en) | 2019-11-26 | 2021-05-27 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
EP4126824A1 (en) | 2020-03-31 | 2023-02-08 | Theravance Biopharma R&D IP, LLC | Substituted pyrimidines and methods of use |
MX2022014191A (es) | 2020-05-13 | 2022-12-07 | Massachusetts Inst Technology | Composiciones de microdispositivos polimericos y su uso en la inmunoterapia de cancer. |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CN116323607A (zh) | 2020-06-10 | 2023-06-23 | 施万生物制药研发Ip有限责任公司 | 用作alk5抑制剂的萘啶衍生物 |
WO2022165403A1 (en) | 2021-02-01 | 2022-08-04 | Yale University | Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment |
WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
KR20240099259A (ko) | 2021-10-14 | 2024-06-28 | 아스널 바이오사이언시스, 인크. | 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포 |
EP4197525A1 (en) | 2021-12-20 | 2023-06-21 | Scandion Oncology A/S | Combination of drugs for the treatment of cancer |
CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
WO2023194656A1 (en) | 2022-04-08 | 2023-10-12 | Tilt Biotherapeutics Oy | Monoclonal pd-l1 antibodies |
CN114588258B (zh) * | 2022-05-10 | 2023-04-25 | 中山大学 | Bmp9联合nk细胞和pd-l1抗体在制备肝癌药物方面的应用 |
WO2023242235A1 (en) | 2022-06-14 | 2023-12-21 | Scandion Oncology A/S | Abcg2 inhibitor and nae inhibitor for the treatment of cancer |
WO2024040264A1 (en) | 2022-08-19 | 2024-02-22 | Massachusetts Institute Of Technology | Compositions and methods for targeting dendritic cell lectins |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
WO2024112867A1 (en) | 2022-11-23 | 2024-05-30 | University Of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4230767A (en) | 1978-02-08 | 1980-10-28 | Toyo Boseki Kabushiki Kaisha | Heat sealable laminated propylene polymer packaging material |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4727022A (en) | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
JPS6178686A (ja) | 1984-09-26 | 1986-04-22 | Dainippon Printing Co Ltd | 真空成形用印刷フイルム |
US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
US6235488B1 (en) | 1988-09-29 | 2001-05-22 | Agilent Technologies, Inc. | Surface preparation for chemical-specific binding |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
WO1995003408A1 (en) | 1993-07-26 | 1995-02-02 | Dana-Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
US5954687A (en) | 1995-04-28 | 1999-09-21 | Medtronic, Inc. | Burr hole ring with catheter for use as an injection port |
DE19526386C1 (de) | 1995-07-19 | 1997-01-02 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
EP0969865B1 (en) | 1996-05-23 | 2006-12-06 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
US6103479A (en) * | 1996-05-30 | 2000-08-15 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US6579854B1 (en) | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
US5939281A (en) * | 1996-09-16 | 1999-08-17 | Case Western Reserve University | Detecting alloreactivity |
US6232445B1 (en) * | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
NL1008929C2 (nl) * | 1998-04-20 | 1999-10-21 | Vhp Ugchelen Bv | Uit papier vervaardigd substraat voorzien van een geïntegreerde schakeling. |
AU769538B2 (en) * | 1998-04-24 | 2004-01-29 | Hemosol Inc. | Efficient ex vivo expansion of CD4+ and CD8+ T-cells from HIV infected subjects |
US6406921B1 (en) * | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
US20060205034A1 (en) | 1998-10-30 | 2006-09-14 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
US20030027998A1 (en) | 1998-10-30 | 2003-02-06 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
DE69938871D1 (de) | 1998-12-03 | 2008-07-17 | Univ California | Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
US7041474B2 (en) * | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
WO2000055375A1 (en) | 1999-03-17 | 2000-09-21 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
EP1169347B1 (en) | 1999-04-02 | 2008-07-02 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
RU2182481C2 (ru) * | 1999-08-02 | 2002-05-20 | Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии | Способ лечения злокачественной лимфомы кожи |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
NZ517122A (en) | 1999-08-23 | 2004-02-27 | Dana Farber Cancer Inst Inc | Novel B7-4 molecules and uses therefor |
CA2381770C (en) * | 1999-08-24 | 2007-08-07 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
WO2001021631A2 (en) | 1999-09-20 | 2001-03-29 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
CA2387959A1 (en) | 1999-11-12 | 2001-05-17 | Human Genome Sciences, Inc. | 21 human secreted proteins |
DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
WO2001068134A2 (en) | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
WO2001094413A2 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
ES2402546T3 (es) * | 2000-06-28 | 2013-05-06 | Genetics Institute, Llc | Moléculas PD-L2: nuevos ligandos de PD-1 y usos de lso mismos |
EP1299522B1 (en) * | 2000-06-30 | 2011-11-02 | University Of Louisville Research Foundation, Inc. | Alteration of cell membrane |
US6638915B1 (en) * | 2000-06-30 | 2003-10-28 | Harold Killam | Anti-viral composition |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
CA2422215A1 (en) * | 2000-09-20 | 2002-03-28 | Amgen Inc. | B7-like molecules and uses thereof |
US20030180309A1 (en) | 2001-01-08 | 2003-09-25 | Baum Peter R. | Human B7 polypeptides |
WO2002068647A2 (en) | 2001-01-16 | 2002-09-06 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2002245332A1 (en) | 2001-01-29 | 2002-08-12 | The Center For Blood Research, Inc | Anergy-regulated molecules |
WO2002066045A2 (en) | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc. | Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a |
DK2336167T3 (da) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
WO2002077208A1 (de) | 2001-03-27 | 2002-10-03 | Genethor Gmbh | Antigen-abhängige reduktion von spezifischen immunreaktionen durch beeinflussung der co-stimulation |
AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
WO2002086083A2 (en) | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
FR2824567B1 (fr) | 2001-05-11 | 2003-08-08 | Inst Nat Sante Rech Med | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
WO2002092792A2 (de) | 2001-05-16 | 2002-11-21 | Genethor Gmbh | Antigen-abhängige reduktion von spezifischen immunreaktionen durch beeinflussung der co-stimulation |
US20060276422A1 (en) | 2001-05-18 | 2006-12-07 | Nassim Usman | RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA) |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
GB0116942D0 (en) | 2001-07-11 | 2001-09-05 | Sahajanand Biotech Private Ltd | Herbal formulation |
WO2003006632A2 (en) | 2001-07-12 | 2003-01-23 | Canvac | Methods and compisitions for activation human t cells in vitro |
EP1456652A4 (en) * | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US7638325B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
DK1503794T3 (da) * | 2002-04-12 | 2012-07-23 | Medarex Inc | Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer |
CA2388441A1 (en) | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
US7304149B2 (en) | 2002-06-20 | 2007-12-04 | Washington University In St. Louis | BTLA nucleic acids |
JP4409430B2 (ja) * | 2002-07-03 | 2010-02-03 | 小野薬品工業株式会社 | 免疫賦活組成物 |
JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
WO2004017991A1 (en) * | 2002-08-13 | 2004-03-04 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas |
JP2006512942A (ja) | 2002-10-25 | 2006-04-20 | ユニバーシティー オブ コネティカット ヘルス センター | 制御細胞溶解による癌の免疫療法のための装置と方法 |
US7449300B2 (en) | 2002-11-21 | 2008-11-11 | Mayo Foundation For Medical Education And Research | Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
ES2676503T3 (es) | 2002-12-16 | 2018-07-20 | Globeimmune, Inc. | Vacunas basadas en levadura como inmunoterapia |
ITMI20022758A1 (it) | 2002-12-23 | 2004-06-24 | Isagro Ricerca Srl | Nuovi uracili ad attivita' erbicida. |
JP4511943B2 (ja) * | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
TW579556B (en) * | 2003-03-28 | 2004-03-11 | Au Optronics Corp | Method of fabricating a low temperature polysilicon film |
US20040248205A1 (en) | 2003-04-16 | 2004-12-09 | Stern Lawrence J. | Major histocompatibility complex (MHC)-peptide arrays |
CN1889963A (zh) | 2003-10-10 | 2007-01-03 | 宝德杰克特疫苗有限公司 | 方法 |
MXPA06004680A (es) | 2003-10-27 | 2007-04-17 | Genelabs Tech Inc | Compuestos de nucleosido para el tratamiento de infecciones virales. |
EP1682564A1 (en) | 2003-10-27 | 2006-07-26 | Genelabs Technologies, Inc. | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES |
KR20050041296A (ko) | 2003-10-30 | 2005-05-04 | 학교법인 인제학원 | ΗΒx 단백질을 발현하는 간세포의 완전한 사멸을유도시키는 방법 및 이 방법을 이용하여 세포사멸 억제물질 및 유전자를 탐색하는 방법 |
GB0326168D0 (en) | 2003-11-10 | 2003-12-17 | Arrow Therapeutics Ltd | Chemical compounds |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2005071095A2 (en) | 2004-01-16 | 2005-08-04 | Applera Corporation | Fluorogenic kinase assays and substrates for kinases and phosphatases |
EP3287130A1 (en) | 2004-05-21 | 2018-02-28 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and protease inhibitors |
JP5070045B2 (ja) | 2004-05-27 | 2012-11-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規人工抗原提示細胞およびそれらの用途 |
CA2572467A1 (en) | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
US20090123413A1 (en) | 2004-08-23 | 2009-05-14 | Britta Hardy | Use of bat monoclonal antibody for immunotherapy |
PL1810026T3 (pl) | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
EP2460533A3 (en) | 2004-10-18 | 2014-01-08 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
AU2005321898B2 (en) | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
PL2439273T3 (pl) * | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
CA2545557A1 (en) | 2005-05-31 | 2006-11-30 | Mcgill University | Stromal antigen-presenting cells and use thereof |
KR101514463B1 (ko) | 2005-06-08 | 2015-04-28 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007016340A2 (en) | 2005-07-29 | 2007-02-08 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
JP2009506789A (ja) | 2005-09-06 | 2009-02-19 | キナメッド・インコーポレイテッド | リンパ組織におけるリンパ増殖、クローン拡大、動員および輸送ならびにそれらに対する抗原および調整剤のインビボ作用を定量するためのキネティックバイオマーカー |
JP2007089496A (ja) | 2005-09-29 | 2007-04-12 | Institute Of Physical & Chemical Research | 医薬のスクリーニング方法 |
JP2009521409A (ja) | 2005-12-08 | 2009-06-04 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | 制御性t細胞を増殖する方法と組成物 |
MX2008007292A (es) | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
US20090215084A1 (en) | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
WO2007082144A2 (en) | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
JP5093097B2 (ja) | 2006-03-03 | 2012-12-05 | 小野薬品工業株式会社 | 細胞表面機能分子の細胞外領域多量体 |
EP2007806A2 (en) | 2006-04-13 | 2008-12-31 | ZymoGenetics, Inc. | Tetramerizing polypeptides and methods of use |
WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008085562A2 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
US9018245B2 (en) | 2006-12-26 | 2015-04-28 | Japan Science And Technology | Method for promoting immune response comprising inhibiting CD22 function in B cells |
CA3045637A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
WO2008091643A2 (en) | 2007-01-23 | 2008-07-31 | Altarex Medical Corp. | In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy |
US8455188B2 (en) | 2007-01-26 | 2013-06-04 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
JP5140146B2 (ja) * | 2010-12-09 | 2013-02-06 | 住友ゴム工業株式会社 | 空気入りタイヤ |
JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR20170074235A (ko) * | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
JP6956639B2 (ja) * | 2015-05-01 | 2021-11-02 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 抗ccr4抗体を用いてサイトカイン発現を媒介する方法 |
EP3316902A1 (en) * | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
US20180222982A1 (en) * | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
BR112018006689A2 (pt) * | 2015-10-02 | 2018-10-09 | Dana Farber Cancer Inst Inc | terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle |
CA3033542A1 (en) * | 2016-08-30 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Compositions and uses of biomaterials and activators of innate immunity |
WO2019023525A1 (en) * | 2017-07-28 | 2019-01-31 | Dana-Farber Cancer Institute, Inc. | ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS |
WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
US11674950B2 (en) * | 2017-10-31 | 2023-06-13 | Dana-Farber Cancer Institute, Inc. | Methods determining and treating cellular resistance to ADP-rtbosylating toxin |
WO2019232533A1 (en) * | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof |
-
2006
- 2006-06-08 KR KR1020087000548A patent/KR101514463B1/ko active IP Right Grant
- 2006-06-08 DK DK06784684.0T patent/DK1907000T4/da active
- 2006-06-08 SI SI200632123A patent/SI2397156T1/sl unknown
- 2006-06-08 NZ NZ593388A patent/NZ593388A/xx unknown
- 2006-06-08 EP EP11162667.7A patent/EP2397155B1/en not_active Revoked
- 2006-06-08 LT LTEP11162681.8T patent/LT2397156T/lt unknown
- 2006-06-08 CA CA2981431A patent/CA2981431C/en active Active
- 2006-06-08 CN CN201410597059.3A patent/CN104436190A/zh active Pending
- 2006-06-08 EP EP23163877.6A patent/EP4242655A3/en active Pending
- 2006-06-08 EP EP11162681.8A patent/EP2397156B1/en active Active
- 2006-06-08 WO PCT/US2006/022423 patent/WO2006133396A2/en active Application Filing
- 2006-06-08 KR KR1020147028424A patent/KR101600225B1/ko active Application Filing
- 2006-06-08 ES ES11162681.8T patent/ES2608316T3/es active Active
- 2006-06-08 CN CN201410095192.9A patent/CN103830725A/zh active Pending
- 2006-06-08 SI SI200631501T patent/SI1907000T2/sl unknown
- 2006-06-08 CA CA2611861A patent/CA2611861C/en active Active
- 2006-06-08 PT PT111626818T patent/PT2397156T/pt unknown
- 2006-06-08 PL PL06784684T patent/PL1907000T5/pl unknown
- 2006-06-08 PL PL11162681T patent/PL2397156T3/pl unknown
- 2006-06-08 NZ NZ601439A patent/NZ601439A/xx unknown
- 2006-06-08 DK DK11162681.8T patent/DK2397156T3/en active
- 2006-06-08 JP JP2008515956A patent/JP5788632B2/ja active Active
- 2006-06-08 EP EP16187881.4A patent/EP3130350A1/en not_active Withdrawn
- 2006-06-08 MX MX2015000025A patent/MX351401B/es unknown
- 2006-06-08 SG SG10201702670VA patent/SG10201702670VA/en unknown
- 2006-06-08 RU RU2011133335/15A patent/RU2596491C2/ru active
- 2006-06-08 NZ NZ564243A patent/NZ564243A/en unknown
- 2006-06-08 KR KR1020167004817A patent/KR101804078B1/ko active IP Right Grant
- 2006-06-08 CN CNA2006800270076A patent/CN101355965A/zh active Pending
- 2006-06-08 KR KR1020147003918A patent/KR101510065B1/ko active IP Right Grant
- 2006-06-08 US US11/449,919 patent/US8652465B2/en active Active
- 2006-06-08 EP EP06784684.0A patent/EP1907000B2/en active Active
- 2006-06-08 NZ NZ590308A patent/NZ590308A/en unknown
- 2006-06-08 MX MX2012004075A patent/MX349137B/es unknown
- 2006-06-08 HU HUE11162681A patent/HUE030877T2/en unknown
- 2006-06-08 ES ES06784684T patent/ES2397355T5/es active Active
- 2006-06-08 AU AU2006254902A patent/AU2006254902B8/en active Active
- 2006-06-08 RU RU2007147642/15A patent/RU2434641C2/ru active
- 2006-06-08 BR BRPI0611766-0A patent/BRPI0611766A2/pt not_active Application Discontinuation
-
2007
- 2007-12-09 IL IL187999A patent/IL187999A/en active IP Right Grant
- 2007-12-18 ZA ZA2007/10975A patent/ZA200710975B/en unknown
-
2008
- 2008-10-08 HK HK08111142.6A patent/HK1115326A1/xx active IP Right Maintenance
-
2012
- 2012-05-29 JP JP2012121491A patent/JP5753819B2/ja active Active
-
2013
- 2013-07-04 JP JP2013140306A patent/JP5882954B2/ja active Active
- 2013-12-30 US US14/144,304 patent/US9457080B2/en active Active
-
2014
- 2014-01-09 IL IL230396A patent/IL230396A/en active IP Right Grant
-
2015
- 2015-01-19 IL IL236805A patent/IL236805B/en active IP Right Grant
- 2015-01-19 IL IL236806A patent/IL236806A/en active IP Right Grant
- 2015-06-04 JP JP2015113648A patent/JP6494434B2/ja active Active
-
2016
- 2016-07-28 RU RU2016131170A patent/RU2746383C2/ru active
- 2016-08-30 US US15/252,133 patent/US10370446B2/en active Active
- 2016-12-14 JP JP2016242046A patent/JP2017075168A/ja active Pending
-
2017
- 2017-01-16 CY CY20171100050T patent/CY1118612T1/el unknown
-
2018
- 2018-02-20 IL IL257622A patent/IL257622B/en active IP Right Grant
- 2018-02-27 JP JP2018032729A patent/JP2018109045A/ja not_active Withdrawn
-
2019
- 2019-06-18 US US16/445,130 patent/US11359013B2/en active Active
- 2019-12-25 JP JP2019233736A patent/JP2020073527A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2723050C2 (ru) * | 2013-05-02 | 2020-06-08 | Анаптисбайо, Инк. | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011133335A (ru) | Способы и композиции для лечения персистирующих инфекций | |
JP2008543774A5 (ru) | ||
Hryniewicz et al. | CTLA-4 blockade decreases TGF-β, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques | |
MARTIN et al. | Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody | |
RU2019101804A (ru) | Комбинированная терапия | |
RU2020115527A (ru) | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор | |
RU2016107426A (ru) | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета | |
Klein et al. | A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity | |
MX2008000984A (es) | Metodos para reducir la carga viral en pacientes infectados con vih-1. | |
Geng et al. | B7‐H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL‐10 levels | |
Rudolph et al. | Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo | |
Schade et al. | Programmed death 1 expression on CD4+ T cells predicts mortality after allogeneic stem cell transplantation | |
Macatangay et al. | Regulatory T cells in HIV immunotherapy | |
Noto et al. | B-cell abnormalities and impact on antibody response in HIV infection | |
BR9709524A (pt) | Anticorpos contra um complexo de cd4 e um domìnio receptor de quimiocina e seu uso contra infecções de hiv | |
Nanan et al. | Measles virus infection causes transient depletion of activated T cells from peripheral circulation | |
Tamburini | Contributions of PD‐L1 reverse signaling to dendritic cell trafficking | |
Anderko et al. | Mapping the interplay between NK cells and HIV: therapeutic implications | |
de Bree et al. | B cells in HIV pathogenesis | |
Goto et al. | Programmed death-ligand 1 on antigen-presenting cells facilitates the induction of antigen-specific cytotoxic T lymphocytes: application to adoptive T-cell immunotherapy | |
Macatangay et al. | PD-1 blockade: A promising immunotherapy for HIV? | |
WO2010104617A2 (en) | Novel methods to induce a state of immune tolerance | |
Panetti et al. | Dampening antiviral immunity can protect the host | |
Akari et al. | Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86 | |
Derrien et al. | Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro |